二甲双胍联合艾塞那肽治疗新诊断超重2型糖尿病的疗效观察

发布时间：2018-12-15 08:04

【摘要】：目的评估二甲双胍联合艾塞那肽治疗新诊断超重2型糖尿病(T2DM)患者的疗效及安全性,并观察经该降糖方案治疗12周后停用艾塞那肽,患者各指标的变化。方法选取新诊断超重T2DM患者50例为研究对象,检测治疗前、二甲双胍联合艾塞那肽治疗12周及停用艾塞那肽12周患者体质量、体质指数(BMI)、空腹及餐后2 h血浆葡萄糖水平、糖化血红蛋白(HbA_(1c))、三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL)、空腹胰岛素、空腹C肽、餐后2 h C肽、脂联素、抵抗素、肿瘤坏死因子(TNF)-α等指标,计算胰岛素抵抗指数(HOMA-IA)。采用配对t检验比较治疗前与治疗12周、治疗12周与停用艾塞那肽12周上述指标的差异。结果二甲双胍联合艾塞那肽治疗12周可降低T2DM患者体质量、BMI、空腹及餐后2 h血浆葡萄糖、HbA_(1c)、TG、TC、LDL、HOMA-IR、抵抗素、TNF-α,升高脂联素,差异均有统计学意义(P0.05)。停用艾塞那肽12周后,空腹及餐后2 h血浆葡萄糖、HbA_(1c)、HOMA-IR、TNF-α较联合治疗12周时升高,差异有统计学意义(P0.05);其余指标差异均无统计学意义(P0.05)。结论对新诊断超重T2DM患者,早期二甲双胍联合艾塞那肽可能是一种安全、有效的治疗方案。
[Abstract]:Objective to evaluate the efficacy and safety of metformin combined with esenapeptide in the treatment of newly diagnosed overweight type 2 diabetes mellitus (T2DM). Methods 50 newly diagnosed overweight T2DM patients were studied. Before treatment, metformin combined with esenapeptide was used for 12 weeks and the body mass and body mass index (BMI),) of patients with isenapeptide were stopped for 12 weeks. Fasting and 2 h postprandial plasma glucose levels, HbA_ (1 c), triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL), fasting insulin, fasting C-peptide, 2 h postprandial C-peptide, adiponectin). Resistin and tumor necrosis factor (TNF)-伪 were used to calculate insulin resistance index (HOMA-IA). Paired t test was used to compare the above indexes between 12 weeks of treatment and 12 weeks of treatment, 12 weeks of treatment and 12 weeks of discontinuation of isenapeptide. Results Metformin combined with esenapeptide could decrease the body mass of T2DM patients for 12 weeks. Plasma glucose, HbA_ (1c), TG,TC,LDL,HOMA-IR, resistin, TNF- 伪 and adiponectin were increased in fasting and 2 h postprandial BMI, patients. The difference was statistically significant (P0.05). The levels of plasma glucose, HbA_ (1c) and HOMA-IR,TNF- 伪 in fasting and 2 h postprandial group were significantly higher than those at 12 weeks after treatment (P0.05). There was no significant difference in other indexes (P0.05). Conclusion early metformin combined with esenapeptide may be a safe and effective treatment for newly diagnosed overweight T2DM patients.
【作者单位】：海南省人民医院内分泌科;
【基金】：海南省重点科技计划项目(ZDXM20120114)
【分类号】：R587.1

【相似文献】